The Experts below are selected from a list of 117 Experts worldwide ranked by ideXlab platform

Paul J Gaglio - One of the best experts on this subject based on the ideXlab platform.

Xiaodong Wu - One of the best experts on this subject based on the ideXlab platform.

  • case control study of the association between select hla genes and anti Erythropoietin Antibody positive pure red cell aplasia
    Pharmacogenomics, 2008
    Co-Authors: Bonnie Fijal, Deborah Ricci, Els Vercammen, Peter A Palmer, Fotis Fotiou, Daniel Fife, Anders Lindholm, Erin Broderick, Stephan Francke, Xiaodong Wu
    Abstract:

    Aims: Antibody (Ab)-positive pure red-cell aplasia (PRCA) is a very rare but serious adverse event associated with recombinant human Erythropoietin treatment (4.1 reports per 100,000 patient-years) in which patients produce antibodies to recombinant and endogenous Erythropoietin, halting red blood cell production. In a previous case series, four Thai subjects with chronic kidney disease and Ab-positive PRCA were reported to have the HLA-DRB1*9 allele. To confirm a possible association of HLA-DRB1*9 and Ab-positive PRCA, we performed a pharmacogenomic analysis using subjects from an earlier case–control study of risk factors associated with Ab-positive PRCA, which had been performed using subjects from Europe or Canada. The primary goal of the analysis was to test the association between HLA-DRB1*9 and Ab-positive PRCA. A secondary goal was to perform an exploratory analysis in order to identify additional HLA alleles potentially associated with Ab-positive PRCA. Patients & Methods: Subjects were taken fro...

Seiichi Motomura - One of the best experts on this subject based on the ideXlab platform.

  • early onset of anti Erythropoietin Antibody mediated pure red cell aplasia after commencement of subcutaneous administration of epoetin β
    The Japanese journal of clinical hematology, 2012
    Co-Authors: Aya Tanaka, Junichi Tsukada, Hiroaki Morimoto, Takefumi Katsuragi, Tsukasa Nakanishi, Shu Watanabe, Nobuhisa Hirase, Seiichi Motomura
    Abstract:

    : We report a 73-year-old Japanese man with early onset pure red cell aplasia (PRCA) caused by subcutaneous administration of recombinant epoetin-β. Two months after the start of epoetin therapy, he developed PRCA. Anti-Erythropoietin (EPO) Antibody, detected in the patient's serum by enzyme immunoassay and radioimmunoprecipitation method, inhibited EPO-dependent growth of AS-E2 cells in vitro. Treatment with prednisone (1 mg/kg) significantly reduced Antibody levels 3 months later. It is important to have an awareness of Antibody-mediated PRCA. Our case shows that subcutaneous epoetin administration produces this complication in the early period of therapy.

Takayuki Ishikawa - One of the best experts on this subject based on the ideXlab platform.

  • successful treatment of anti Erythropoietin Antibody mediated pure red cell aplasia with low dose prednisolone
    International Journal of Hematology, 2013
    Co-Authors: Kazunari Aoki, Sumie Tabata, Akiko Matsushita, Takayuki Ishikawa
    Abstract:

    The standard therapy for anti-Erythropoietin (EPO) Antibody-mediated pure red cell aplasia (PRCA) is cyclosporine (CyA) or prednisolone (PSL) 0.5–1.0 mg/kg. However, many patients with severe chronic kidney disease (CKD) and chronic heart failure cannot tolerate such an immunosuppressive regimen. An 86-year-old man with anemia related to CKD and chronic heart failure, who had received recombinant human Erythropoietin subcutaneously, developed anti-EPO Antibody-mediated PRCA. The patient was treated with CyA followed by PSL (1.0 mg/kg); however, he was unable to tolerate this drug regimen. The PSL dose was reduced to 0.2 mg/kg. Surprisingly, his reticulocyte count increased 3 months later, and RBC transfusion was no longer required. Low-dose PSL is a treatment option for patients with anti-EPO Antibody-mediated PRCA who cannot tolerate CyA and PSL (0.5–1.0 mg/kg).

Jordan M Schecter - One of the best experts on this subject based on the ideXlab platform.